Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules

Cancer Research

Volumn 58, Issue 20, 1998, Pages 4567-4571

  Zajac, Paul ^a,b   Schütz, Alexander ^a   Oertli, Daniel ^a   Noppen, Christoph ^a   Schaefer, Christoph ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a   Marti, Walter R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ZLF   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE CONSTRUCT; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINIA VIRUS; VIRUS GENE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; IMMUNOTHERAPY; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; ULTRAVIOLET RAYS; VACCINIA VIRUS;

EID: 0032532615     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
2. June, C. H., Bluestone, J. A., Nadler, L. M., and Thompson, C. B. The B7 and CD28 receptor families. Immunol. Today, 15: 321-331, 1994.
3. Judge, T. A., Tang, A., and Turka, Ł. A. Immunosuppression through blockade of CD28: B7-mediated costimulatory signals. Immunol. Res., 15: 38-49, 1996.
4. Bellone, M., lezzi, G., Manfredi, A. A., Protti, M. P., Dellabona, P., Casorati, G., and Rugarli, C. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur. J. Immunol., 24: 2691-2698, 1994.
5. Dohring, C., Angman, L., Spagnoli, G. C., and Lanzavecchia, A. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer, 57: 754-759, 1994.
6. Yang, S., Darrow, T. L., and Seigler, H. F. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class-I matched allogenic peripheral blood lymphocyte by B7 gene-modified melanoma cells. Cancer Res., 57: 1561-1568, 1997.
7. Restifo, N. P. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol., 8: 658-663, 1996.
8. Paoletti, E. Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA, 93: 11349-11353, 1996.
9. Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA, 93: 11341-11348, 1996.
10. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific tor human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine [see comments]. J. Natl. Cancer Inst., 87: 982-990, 1995.
11. Zajac, P., Oertli, D., Spagnoli, G. C., Noppen, C., Schaefer, C., Heberer, M., and Marti, W. R. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope. Int. J. Cancer, 71: 491-496, 1997.
12. Marti, W. R., Zajac, P., Spagnoli, G. C., Heberer, M., and Oertli, D. Non-replicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitra. Cell Immunol., 179: 146-152, 1997.
13. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
14. Spagnoli, G. C., Schaefer, C., Willimann, T. E., Kocher, T., Amoroso, A., Juretic, A., Zuber, M., Luscher, U., Harder, F., and Heberer, M. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer, 64: 309-315, 1995.
15. Tsung, K., Yim, J. H., Marti, W. R., Buller, M. L., and Norton, J. A. Gene expression and cytopathic effect of chemically inactivated vaccinia virus. J. Virol., 70: 165-171, 1996.
16. Coupar, B. E., Andrew, M. E., Both, G. W., and Boyle, D. B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol., 16: 1479-1487, 1986.
17. Demkowicz, W. E., Maa, J. S., and Esteban, M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J. Virol., 66: 386-398, 1992.
18. Demkowicz, W. E., and Ennis, F. A. Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J. Virol., 67: 1538-1544, 1993.
19. Abe, R., Vandenberghe, P., Craighead, N., Smoot, D. S., Lee, K. P., and June, C. H. Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation. J. Immunol., 154: 985-997, 1995.
20. Deeths, M. J., and Mescher, M. F. B7-1 dependent costimulation result in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur. J. Immunol., 27: 598-608, 1997.
21. Oertli, D., Marti, W. R., Norton, J. A., and Tsung, K. Artificial antigen presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+ lymphocytes in vitro. Clin. Exp. Immunol., 110: 144-149, 1997.
22. Noppen, C., Schaefer, C., Zajac, P., Schütz, A., Kocher, T., Kloth, J., Heberer, M., Colonna, M., De Libero, G., and Spagnoli, G. C. C-type lectin-like receptors in peptide specific HLA-class I restricted cytotoxic T lymphocytes: differential expression and modulation of effector functions in clones sharing identical TCR structure and epitope specificity. Eur. J. Immunol., 28: 1134-1142, 1998.
23. Chamberlain, R. S., Carroll, M. W., Bronte, V., Hwu, P., Warren, S., Yang, J. C., Nishimura, M., Moss, B., Rosenberg, S. A., and Restifo, N. P. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res., 56: 2832-2836, 1996.
24. Hodge, J. W., McLaughlin, J. P., Abrams, S. I., Shupert, W. L., Schlom, J., and Kantor, J. A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res., 55: 3598-3603, 1995.
25. Cooney, E. L., Collier, A. C., Greenberg, P. D., Coombs, R. T., Zarling, J., Arditti, D. E., Hoffman, M. C., Hu, S. L., and Corey, L. Safety and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet, 337: 567-572, 1991.